To the extended PM Holding family,
As I write this year’s letter, it occurs to me just how big the PM Holding “family” has become over the years. Arithmos company started its independent journey in 2010, as a startup “spin-off” of the CROS NT (now part of Alira Health) internal IT department.
In our 12-year journey, the Arithmos family now includes its colleagues and sister companies under PM Holding, the numerous partners and consultants who helped us achieve a high standard of quality, value and international recognition, and of course, our numerous clients over the years who have always believed in the power of technology and digital transformation as an engine of growth for the Life Sciences industry.
Here we are, wrapping up our twelfth year, in what I can only describe as a year of consolidated growth and business expansion. While our team certainly still has that “start-up spirit” of wanting to constantly innovate and find new solutions for our customers, Arithmos is now an established player in technology and business solutions and consultancy for Life Sciences while carving out a niche for itself in terms of expert pharmacovigilance and quality services. This is where Arithmos shines: at the intersection of technology-enabled solutions and quality compliance.
The key to our growth this year was focus, especially on getting the business model right.
This summer, we successfully merged Arithmos and seQure, seQure being the last piece of the PM Holding puzzle as a niche provider of Pharmacovigilance, Quality Assurance Compliance in the GxP environment.
Later in the year, we acquired The CQA Company in the UK, a Quality Assurance consultancy company, with a solid expertise in Good Manufacturing Practices (GMP) quality and compliance services, to bolster our service offering in terms of digital transformation and consultancy.
Arithmos’ path from IT experts to technology partners to “Quality Compliance and Technology Consultancy” company for Life Sciences is no accident. We have always seen the need and benefit of technology in Life Sciences to get treatments and therapies to patients faster and more effectively, but we also know that with great innovation comes great responsibility, which is why we also want to support companies in meeting quality and safety standards that the sector demands and patients expect when it comes to their health.
How did we get here and where are we going?
We are dedicated to bettering the field of Life Sciences, and we have a strong network of partners built over the years that help us achieve that goal. In the past couple of years, extraordinary events only amplified the need for technology, which means a heightened sense of quality, safety and, of course, security. I am confident in saying, we now have all the bases covered.
Our 2023 will be further dedicated to consolidating our efforts in technology and business consultancy while guiding our customers through the regulatory requirements they need to achieve optimal results.
As they say, it takes a village…
CEO of PM Holding